Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting

Salil V. Deo, Sadeer Al-Kindi, Salim S. Virani, Stephen Fremes

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)723-730.e4
JournalJournal of Thoracic and Cardiovascular Surgery
Volume167
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • PSCK9 inhibitor
  • atherosclerosis
  • bempedoic acid
  • coronary artery bypass grafting
  • coronary artery disease
  • ezetimibe
  • inclisiran
  • statin intolerance
  • statin-associated muscle symptoms
  • Anticholesteremic Agents
  • Humans
  • Cholesterol, LDL
  • Hypercholesterolemia
  • Coronary Artery Bypass/adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this